Original Article

Running Title: A Novel Combination of Gallic Acid and Dexamethasone
Received: June 24, 2019; Accepted: April 26, 2020

A Novel Combination of Pterostilbene and Dexamethasone Enhances Anti-proliferation and Apoptosis Induction Properties in Lymphoblastic Leukemia Cell Line

Zahra Sourani*, Zahra Rezaei Dezaki**, Tahereh Rahimnejad***, Batoul Pourghesari****
* Medical Plant Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
** Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
*** Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
**** Pathology and Hematology Department, Shahrekord University of Medical Sciences, Shahrekord, Iran

* Corresponding Author
Batoul Pourghesari, PHD
Pathology and Hematology Department, Shahrekord University of Medical Sciences, Shahrekord, Iran
Tel: +989133031381
Email: bat238@yahoo.com

Abstract

Background: T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy that results from the transformation of T-cell progenitors. Despite the significant advances in the current treatments, the side effects of conventional chemotherapy regimens are still a major concern. Pterostilbene (PT) is a natural compound reported to have anti-tumor effects. This study aimed to investigate the effect of PT combined with dexamethasone on the proliferation inhibition and apoptosis stimulation in a lymphoblastic leukemia cell line.

Methods: In this experimental study, we cultured Jurkat cell line in RPMI1640 culture medium under standard conditions. We incubated the cells with different concentrations of PT and dexamethasone separately or in combination for 48 h. MTS assay investigated the cell viability. We assessed apoptosis induction by annexin V-FITC/PI and flow cytometry analysis.

Results: PT and dexamethasone reduced the viability of the cells with inhibition concentrations of 60.97±3.36 and 451.1±10.1 µM, respectively, in 48 hours. None of the concentrations of dexamethasone, employed alone, significantly reduced the cell viability. The combination of 450 µM dexamethasone with 60 µM PT induced apoptosis in more than 70% of the cells with a significant difference compared to control.

Conclusion: PT increased the anti-proliferative and apoptosis-inducing activity of dexamethasone in Jurkat cell line. This combination drug strategy can be a novel approach for a more powerful anti-cancer therapy.

Keywords: Apoptosis, Jurkat cell line, T-ALL, Dexamethasone, Pterostilbene
Introduction

Acute lymphoblastic leukemia (ALL) is a hematological malignancy affecting the lymphoblastic lineage. Depending on the type of lymphoblastic lineage involved, ALL can be subdivided into T-cell ALL (T-ALL) and B-cell ALL (B-ALL). T-ALL accounts for approximately 20% of adult and 10-15% of childhood ALL cases. Malignant transformation of T-cells may occur at any stage of maturation, leading to the marked heterogeneity of this leukemia. This aggressive malignancy typically displays a very active proliferative level, a high tumor burden, numerous large thymic masses, and pleural effusions. Despite the significant improvement in the current treatments, T-ALL still remains a leading cause of cancer-related mortality in pediatrics. Prognosis in the elderly is still very poor. Therefore, novel therapeutic approaches are still needed regarding patients unresponsive to conventional chemotherapy.

A favorable attitude for cancer prevention is introducing drugs that block the expansion of cancer. Several extracts of medicinal plants were applied to overcome multidrug resistance. Plant-derived components have been known to exert some effects on blood cells and factors. Natural polyphenols affect various stages of cell cycle and proliferation.

Resveratrol, the most investigated polyphenol, is a promising chemo-protective agent for cancer treatment. It is considered as an effective anti-tumor agent owing to its low toxicity and ability to regulate complex cancer-associated molecular pathways.

Pterostilbene (PT) (trans-3, 5-dimethoxy-4-hydroxystilbene) is a natural dimethylated analog of resveratrol and an anti-tumor compound derived from grapes and other foods. Similar to resveratrol, PT induces apoptosis and has antioxidant, anti-cancer, anti-inflammatory, and anti-proliferation properties. PT has more oral uptake and bioavailability compared with resveratrol. In previous reports, PT induced cancer cell apoptosis in breast, liver, ovarian, and lung malignancies.

At the beginning of treatment with ALL, dexamethasone was increasingly used in the intensification phase of the disease. In this study, for the first time, we examined the effect of PT in combination with dexamethasone on the cell proliferation and apoptosis induction in T-lymphoblastic cell line.

Materials and Methods

In the present experimental study, we investigated the effect of PT combined with dexamethasone on the proliferation inhibition and apoptosis stimulation in a Jurkat cell line.
Cell culture

The National Cell Bank of Iran (Pasteur Institute of Iran, Tehran) provided the human T-cell leukemia cell line (Jurkat). Cells were grown in RPMI1640 culture medium supplemented with 10% fetal calf serum, 0.3 mg/ml glutamine, 100 IU penicillin, and 100 µg/ml streptomycin; they were then incubated in a humidified atmosphere containing 5% CO2 at 37°C.

Cell viability test

We applied MTS to evaluate cell viability according to a previously described method. We cultured Jurkat cells in a concentration of 10^4 cells per well in 96-well plates and kept them for 24 h. We treated the cells with different concentrations of PT (0-100 µM), dexamethasone (0.01-1 IU/ml), or their combination for 48h. Following the incubation time, we added 20 µl of MTS to each well and incubated the cells for 3 h more at 37°C in a dark place. Finally, we measured the absorbance at 490-620 nm by an Elisa reader (stat fax-2100 awarenes).

Apoptosis Assay

We measured apoptosis via flow cytometry with the FITC Annexin V propidium iodide (PI) Apoptosis Detection Kit (BD Pharmingen). Briefly, we implanted jurkat cells in a six-well plate in complete media for 24 h. Afterwards, the cells were treated with different concentrations of PT for 48 h, harvested, and washed twice in cold PBS. We re-suspended 10^6 cells in 1 ml of 1X binding buffer. Next, we incubated 10^5 cells with 5 µl of FITC-labeled annexin V and PI (propidium iodide) at room temperature in darkness for 20 min; after that, we added 400 µl of 1X binding buffer. Ultimately, we evaluated the cells by flow cytometry. For comparison, we used the untreated sample as negative control.

Statistical Analysis

We repeated all experiments at least three times. Statistical analysis was performed by SPSS using Kruskal-Wallis multiple comparison and Dunn’s test. We analyzed the inhibitory concentration of 50% (IC50) value using probit analysis. We used Flowing software for flow cytometric analysis and GraphPad prism for graphs.

Results

Cell viability decreased in the presence of dexamethasone or PT

To determine the effect of dexamethasone on the viability of Jurkat cells, we incubated them for 48 h in the absence or presence of dexamethasone at different concentrations (0–500 µM). The ODs obtained from the absorption at 490 nm were adapted to a percentage. Figure 1 shows the reduction in cell viability with the increase in concentration (dose-dependent) with an IC50 (inhibition concentration) of 451.1±10.1 µM.
Cell viability also decreased in a dose-dependent manner in the treatment by PT with an IC50 of 60.97±3.36 µM.

**PT enhanced the effect of dexamethasone on Jurkat cells**

We assessed cell viability in the presence of different combinations of PT and dexamethasone. We detected a stronger cytotoxicity in all combinations compared to the separate use of each drug (Figure 2). Dexamethasone alone did not make any significant differences compared to the control at any of the used concentrations; however, 450 µM dexamethasone combined with 20, 40, and 60 µM PT as well as 350 µM dexamethasone in combination with 60 µM PT, resulted in a significant difference compared to the control.

**PT or dexamethasone enhanced the apoptosis of Jurkat cells**

We evaluated apoptosis induction via annexin-V/PI apoptosis detection kit. We incubated the cells for 48 h at various concentrations (46, 60, and 80 µM) of PT or dexamethasone (250, 350, and 450). At the above concentrations, PT induced apoptosis in 27, 49, and 60% of the cells in a dose-dependent manner. Apoptosis further increased in dexamethasone-treated cells in a dose-dependent pattern; however, it did not reach a significant level compared to the control.

**PT potentiated the apoptosis induced by dexamethasone**

Figure 3 shows the effect of combination treatment on apoptosis induction. Induction of apoptosis in treated cells augmented in certain combinations. 60 µM PT and 450 µM dexamethasone did not separately cause a significant difference in comparison with control; however, their combination significantly enhanced the apoptosis (Figure 4).

**Discussion**

In the present work, the decrease in cell viability by dexamethasone alone had no significant difference with the control; however, the combination of 450 µM dexamethasone with 20, 40, and 60 µM PT as well as 350 µM dexamethasone with 60 µM PT significantly reduced the cell viability.

At 80 µM concentration, PT separately caused a significant apoptosis, but none of the used concentrations of dexamethasone alone caused such a difference. The combination of 450 µM dexamethasone with 60 µM PT led to a significant difference with the control; however, none of them exerted such an effect when applied separately.

The effect of PT on cell growth inhibition was studied on different cell lines. Wang et al. found the most inhibition after 72 hours with 50 µM concentration on breast cancer cells. They also observed cell cycle arrest at G1. Induction of
apoptosis in cancer cells is a mechanism for preventing or treating cancer. Roslie et al. studied K562 chronic myelogenous leukemia cell line; they detected the highest apoptosis induction at 75 µM and 100 µM PT. This is comparable to our findings regarding lymphoblastic cells and more than what we observed with 100 µM atoposide. In their study, caspase-3 and 9 had the most increase after two hours of treatment with PT. At 75-100 µM, PT reduced cell viability in pancreatic cell lines and induced cell cycle arrest and caspases activation. IC50 of pterostilbene is variable in different cell lines. PT effect was studied on seven cell lines, including human drug resistant myeloid cells. Tolomeo et al. reported that PT had a dose-dependent inhibitory effect on cell growth.

The combination effects of a PT and a chemotherapy reagent was also studied in some other cell lines. Mannal et al. demonstrated the combination effect of PT and tamoxifen on the proliferation inhibition and apoptosis induction of breast cancer cell lines. Their combination was significantly different with the separate application of tamoxifen. This effect was further observed in certain other combinations of a plant-derived component with a chemotherapy reagent. Soltani et al. found this effect in the treatment of lymphoblastic leukemia cells with a combination of thymoquinone and doxorubicine. We already demonstrated enhanced apoptosis and Fas expression both at mRNA level and surface, upon the treatment of the cells with a combination of gallic acid and L-asparaginase on these cells compared to the latter alone. Here, for the first time, we showed the improved anti-proliferative effect of dexamethasone combined with PT on lymphoblastic leukemia cells. The effect of this component on other T-cell lines and T-lymphoblasts needs to be further investigated.

**Conclusion**

Certain combinations of dexamethasone and PT (not dexamethasone alone) reduced the cell viability. This effect might be the result of apoptosis; however, other mechanisms may be involved. PT can be considered in combination chemotherapy of ALL; but, it is necessary to conduct more comprehensive studies on the leukemic cells of patients as well as in vivo in experimental models. The interaction of PT with other components of combination therapy needs to be further investigated.

**Acknowledgement**

The Medical Plants Research Center of Shahrekord University of Medical Sciences supported the present study. The authors wish to thank the Deputy of Research, Shahrekord University of Medical Sciences, for the financial support.

**Conflicts of Interest**

None declared.
References


Figure 1. Effect of dexamethasone or pterostilbene on jurkat cell viability. We incubated the cells with different concentrations of dexamethasone or PT for 48 hours and performed MTS assay to identify the viable cells. The cell viability decreased in a dose-dependent manner. We performed all experiments at least three times.
Figure 2. Cell viability in the presence of dexamethasone in combination with PT. We detected cell viability following 48 hours of incubation with different concentrations of dexamethasone alone or combined with different concentrations of PT. We performed each experiment three times or more and compared cell viability to control. Cell viability decreased significantly when 450 µM of Dexamethasone was combined with 20, 40, and 60 µM of PT or 350 µM of Dexamethasone was combined with 60 µM of PT. (* indicates a significant difference with the controls and P<0.05).
Figure 3. Flow cytometric analysis of apoptosis in the presence of dexamethasone alone or combined with PT. We incubated the cells for 48 hours in the presence of different concentrations of dexamethasone alone or in combination with PT. In the presence of dexamethasone, apoptosis increased in a concentration-dependent manner; however, we observed more apoptosis when 450 µM concentration of dexamethasone was combined with 60 µM of PT (76.66 %).
Figure 4. Comparative analysis of apoptosis in the presence of dexamethasone or in combination with PT. We treated Jurkat cells with different concentrations of dexamethasone alone or 450 µM in combination with 60µM concentration of PT for 48 hours; we stained the cells with FITC-conjugated annexin V and analyzed them by flowcytometry. Untreated cells were considered as controls. A significant difference existed between the control and 450 µM dexamethasone combined with 60 µM PT ($P<0.01$).